To keep up with the latest from FIP, follow us on social media!
More effective and less toxic treatment for breast cancer patients could be on its way, led by the work of Indonesian scientists presented at the World Congress of Pharmacy and Pharmaceutical Sciences today.
Researchers from the Faculty of Pharmacy at the University of Indonesia have developed and validated a combined liquid chromatography-mass spectrometry (LC-MS/MS) method to analyse levels of metabolites of two cancer drugs tamoxifen and doxorubicin.
With tamoxifen, reduction of cancer recurrence occurs via the presence of the metabolites endoxifen (END) and 4-hydroxytamoxifen, and with doxorubicin, the main metabolite is cardiotoxic.
Professor Michael Ward, co-chair of the FIP Congress Programming Committee said: “This research shows how pharmaceutical science research could be applied in practice to individualise chemotherapy or for therapeutic drug monitoring that could increase the survival rate of breast cancer patients.”